Cortex Pharm Inc (CORX) 0.0200 $CORX
RespireRx Pharmaceuticals Inc. Files December 31, 2015 Annual Report on Form 10-K
Marketwired - Tue Mar 29, 12:51PM CDT
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"
, a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its December 31, 2015 Annual Report on Form 10-K and is hereby providing an update on the Company's current operations and its plans for 2016.
Cortex Pharmaceuticals, Inc. Announces Name Change and Symbol Change
Marketwired - Thu Dec 17, 7:01AM CST
Cortex Pharmaceuticals, Inc. (OTC: CORX) (the "Company" is providing investors and shareholders with a 2015 year-end update and a summary overview of the Company's clinical trial plans for 2016.
Respiratory Depression Pipeline Review, H2 2015 - 2 Companies & 6 Drug Profiles
M2 - Fri Nov 06, 10:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxch3b/respiratory) has announced the addition of the "Respiratory Depression - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals Drug Profiles - CX-1739 - CX-1942 - CX-2007 - CX-2076 - GAL-021 - tianeptine For more information visit http://www.researchandmarkets.com/research/kx...espiratory
Cortex Pharmaceuticals, Inc. to Present at the 14th Annual BIO Investor Forum
Marketwired - Mon Oct 19, 7:30AM CDT
Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, particularly obstructive and central sleep apneas and drug-induced respiratory depression, announces that it will be presenting at the 14th Annual BIO Investor Forum (www.bio.org). The conference is being sponsored by the Biotechnology Industry Organization and is being held on October 20 - 21, 2015 at the Parc 55 Hotel, San Francisco, California. The Company's CEO, James S. J. Manuso, Ph.D. is scheduled to present at 11:30 a.m. West Coast Time on Tuesday, October 20, 2015.
Global Sleep Apnea Pipeline Review, H2 2015 - 5 Companies & 12 Drug Profiles
M2 - Fri Oct 02, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lb5jgx/sleep_apnea) has announced the addition of the "Sleep Apnea - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals - Rottapharm SpA - SK Biopharmaceuticals Co., Ltd. - Vivus, Inc. Drug Profiles - (phentermine topiramate) ER - CX-1739 - CX-2007 - CX-2076 - dexloxiglumide - dronabinol - GAL-021 - GAL-160 - GAL-160 Backups - itriglumide - SKL-N05 - Small Molecules for Sleep Apnea For more information visit http://www.researchandmarkets.com/research/lb...leep_apnea
Spinal Cord Injury - Pipeline Review H2 2015
M2 - Fri Oct 02, 5:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42rsjm/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Asubio Pharma Co., Ltd. - Athersys, Inc. - Axerion Therapeutics, Inc. - BioArctic Neuroscience AB - Cortex Pharmaceuticals, Inc. - Faron Pharmaceuticals Oy - FirstString Research, Inc. - Genervon Biopharmaceuticals, LLC - Grupo Ferrer Internacional, S.A. - Hemostemix Ltd - Histocell S.L. - K-Stemcell Co., Ltd. - Kadimastem Ltd. - Kringle Pharma, Inc. - Lipopharma Therapeutics SL - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuronax SAS - Omeros Corporation - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Q Therapeutics, Inc. - Quark Pharmaceuticals, Inc. - Remedy Pharmaceuticals, Inc. - RhinoCyte, Inc. - SanBio, Inc. - Sirnaomics, Inc. - StemCells, Inc. - Stemedica Cell Technologies, Inc. - TissueGene, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/42...pinal_cord
VRTX: 101.53 (+0.32), ATHX: 1.95 (-0.01), ACOR: 24.22 (+0.20), LPTN: 1.87 (unch), OMER: 11.51 (+0.14), CUR: 0.20 (-0.02)
Cortex Pharmaceuticals, Inc. to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Marketwired - Tue Sep 08, 4:05PM CDT
Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, particularly obstructive sleep and central apneas and drug-induced respiratory depression, announces that it will be presenting at the Rodman & Renshaw 17th Annual Global Investment Conference (www.rodm.com). The conference is being sponsored by H.C. Wainwright & Co. and is being held on September 8 - 10, 2015 at The St. Regis Hotel, New York, New York. The Company's CEO, James S. J. Manuso, Ph.D. is currently scheduled to present at 4:40 p.m. Eastern Time on Thursday, September 10, 2015.
Huntington's Disease - Pipeline Review, H1 2015
M2 - Thu Sep 03, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q79g5p/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Acadia Pharmaceuticals - Addex Therapeutics - BioCrea - BioMarin Pharmaceutical - Cortex Pharmaceuticals - CrystalGenomics - EncephRx - Evotec - F. Hoffmann-La Roche - Galenea - Genervon Biopharmaceuticals - Ipsen - Isis Pharmaceuticals - Kadmon Corporation - KineMed - Living Cell Technologies - Marathon Pharmaceuticals - Medesis Pharma - Neuralstem - Neurimmune - Omeros - Oryzon Genomics - Pfizer - PharmatrophiX - Raptor Pharmaceuticals - reMYND - Sangamo BioSciences - Siena Biotech - Teva Pharmaceutical Industries - Treventis - Ultragenyx Pharmaceutical - uniQure - Vaccinex - Varine - Zenobia Therapeutics For more information visit http://www.researchandmarkets.com/research/q7...untingtons
ACAD: 31.37 (-0.50), BMRN: 92.44 (+0.43), RPTP: 6.78 (+0.03), ISIS: 57.56 (-0.28), SGMO: 4.41 (-0.03), TEVA: 53.86 (+0.44)
Cortex Pharmaceuticals raises USD721,180 from initial closing of private placement
M2 - Tue Sep 01, 10:46AM CDT
Biopharmaceutical company Cortex Pharmaceuticals (OTCQB:CORX) reported on Monday the initial closing of USD721,180 under a private placement of up to USD3m units at USD0.02103 per unit.
Cortex Pharmaceuticals, Inc. Announces Appointment of James S. J. Manuso, Ph.D., as President and Chief Executive Officer, Vice Chairman of the Board of Directors
Marketwired - Wed Aug 19, 7:30AM CDT
Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company" , a leader in the discovery and development of innovative pharmaceuticals for the treatment of breathing disorders, today announced the appointment of James S. J. Manuso, Ph.D., 66, as President and Chief Executive Officer, as well as Vice Chairman and a member of the Board of Directors, of the Company. Dr. Manuso also has agreed to subscribe to purchase newly issued securities of the Company in an amount of $250,000, on terms to be agreed between the parties. Dr. Manuso is currently the Chairman, Chief Executive Officer and sole shareholder of Talfinium Investments, Inc., an investment company focusing on publicly traded companies in the biotechnology and pharmaceutical industries.
Fragile X Syndrome Pipeline Review 2015 - 10 Companies & 20 Company Profiles
M2 - Fri Jul 10, 3:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js4sb7/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aelis Farma S.A.S. - Alcobra Ltd - Confluence Pharmaceuticals LLC - Cortex Pharmaceuticals, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Marinus Pharmaceuticals, Inc. - MI.TO. Technology S.r.L. - Neuren Pharmaceuticals Limited - Selvita SA Drug Profiles - acamprosate calcium - basimglurant - Bryostatin-1 - cercosporamide - CX-929 - Drugs to Inhibit mGluR5 for Fragile X Syndrome - flindokalner - gaboxadol - ganaxolone - Metadoxine ER - minocycline - NNZ-2591 - SEL-203 - Small Molecule for FXTAS - Small Molecule to Activate Epsilon PKC for Fragile X Syndrome - Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Small Molecules to Agonize 5-HT7 for Fragile X Syndrome - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - SRT-278 - trofinetide For more information visit http://www.researchandmarkets.com/research/js4sb7/fragile_x
MRNS: 1.45 (+0.07), ADHD: 5.01 (+0.01), LLY: 80.22 (-0.34)
Cortex Pharmaceuticals, Inc. Announces Partnership With the Knowledge Translation Strategy Unit of the Canadian Institutes of Health Research on the Use of Ampakines in the Alleviation of Respiratory Depression
Marketwired - Tue Jun 30, 8:02AM CDT
Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company" is a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression. The Company owns patents and patent applications for certain families of chemical compounds that claim the chemical structures and their use in the treatment of various disorders. These patents cover, among other compounds, the Company's lead ampakines CX1739 and CX1942 and extend through at least 2028.
Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 92.44 (+0.43), SRPT: 25.26 (+0.46), FOLD: 6.94 (+0.23)
Cortex Pharmaceuticals, Inc. Announces Publication of Research Results on the Use of Ampakines CX1739 and CX717 in the Treatment of Respiratory Disorders
GlobeNewswire - Mon May 04, 8:03AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" announces the recent publication of two key scientific papers co-authored by the Chairman of the Company's Scientific Advisory Board, Dr. John Greer, Ph.D. that show the positive effects of the Company's ampakines CX1739 and CX717 in treating respiratory distress in a perinatal premature rat pup model and a genetic mouse model of Pompe Disease. Cortex is a leader in developing drugs for respiratory disorders, particularly sleep apnea (both obstructive and central) and drug-induced respiratory depression.
Cortex Pharmaceuticals, Inc. to Present at NewYorkBIO 25th Anniversary Conference
GlobeNewswire - Fri May 01, 8:00AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces that it will be presenting at the NewYorkBIO 25 Anniversary Conference (http://conference.newyorkbio.org). The conference will take place on May 4 - 5, 2015 at 10 on the Park @ Time Warner Center.
Global Respiratory Depression Pipeline Review 2015 - 2 Companies & 8 Drug Profiles
M2 - Mon Apr 27, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59hbpn/respiratory) has announced the addition of the "Respiratory Depression - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals Drug Profiles - CX-1739 - CX-1942 - CX-2007 - CX-2076 - doxapram hydrochloride - GAL-021 - GAL-021 Successors - tianeptine For more information visit http://www.researchandmarkets.com/research/59...espiratory
Cortex Pharmaceuticals, Inc. Files December 31, 2014 Annual Report on Form 10-K; Provides Update on Current Status and Activities
GlobeNewswire - Mon Apr 06, 5:00AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" is a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression.
Sleep Apnea Therapeutics Pipeline Review 2015 - 4 Companies & 11 Drug Profiles
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pw3nkj/sleep_apnea) has announced the addition of the "Sleep Apnea - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals - Rottapharm SpA - SK Biopharmaceuticals Co., Ltd. Drug Profiles - CX-1739 - CX-2007 - CX-2076 - dexloxiglumide - doxapram hydrochloride - dronabinol - GAL-021 - GAL-160 - GAL-160 Backups - itriglumide - SKL-N05 For more information visit http://www.researchandmarkets.com/research/pw...leep_apnea
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Report: 2015 Edition
M2 - Wed Feb 18, 6:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/26hd3f/copromotion_and) has announced the addition of the "Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering. The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace. Revised and updated 11th edition, includes: - Trends in co-promotion and co-marketing deals - Co-promotion and co-marketing agreement structure - Co-promotion and co-marketing contract documents - Top co-promotion deals by value - Top co-marketing deals by value - Most active co-promotion dealmakers - Most active co-marketing dealmakers Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2009 to end of December 2014. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in co-promotion and co-marketing dealmaking Chapter 3 - Overview of co-promotion deal structure Chapter 4 - Overview of co-marketing deal structure Chapter 5 - Leading co-promotion deals Chapter 6 - Leading co-marketing deals Chapter 7 - Big pharma co-promotion and co-marketing deals Chapter 8 - Co-promotion agreement contracts directory 2009-2014 Chapter 9 - Co-marketing agreement contracts directory 2009-2014 Companies Mentioned - Abbott - Allergan - Alnylam Pharmaceuticals - Ambit Biosciences - Amgen - Clarient - Columbia Laboratories - Cortex Pharmaceuticals - Eli Lilly - Embryome Sciences - Enanta Pharmaceuticals - Ironwood Pharmaceuticals - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe - NovaBay Pharmaceuticals - Novartis - Novo Nordisk - Procter & Gamble - Roche - Sagent Pharmaceuticals - Sanofi - Synta Pharmaceuticals - Takeda - Takeda Pharmaceutical - Targacept - Teva - Xenoport - Zogenix - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/26...motion_and
AMGN: 173.02 (+0.59), LLY: 80.22 (-0.34), CBRX: 7.36 (+0.45), ENTA: 23.41 (+0.01), AGN: 249.61 (-3.41), JNJ: 123.22 (-0.55), SNTA: 0.34 (+0.07), NVO: 46.18 (-0.28), IRWD: 13.36 (+0.02), MRK: 63.35 (-0.28), SGNT: 21.73 (+0.01), PG: 87.04 (+0.31), NVS: 82.08 (-0.72)
Cortex Pharmaceuticals, Inc. to Present at 7th Annual Biotech Showcase(TM) 2015
GlobeNewswire - Fri Jan 09, 7:07AM CST
Cortex Pharmaceuticals, Inc. (CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces that it will be presenting at Biotech Showcase(TM) 2015 (www.ebdgroup.com/bts/index.php). The conference is co-sponsored by the EBD Group and Demy-Colton Life Sciences Advisors and will be held at the Parc 55 Wyndham San Francisco-Union Square Hotel in San Francisco, California from January 12 - 15, 2015.
RespireRx Pharmaceuticals Inc. Files December 31, 2015 Annual Report on Form 10-K
Marketwired - Tue Mar 29, 12:51PM CDT
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"
, a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its December 31, 2015 Annual Report on Form 10-K and is hereby providing an update on the Company's current operations and its plans for 2016. Cortex Pharmaceuticals, Inc. Announces Name Change and Symbol Change
Marketwired - Thu Dec 17, 7:01AM CST
Cortex Pharmaceuticals, Inc. (OTC: CORX) (the "Company"
is providing investors and shareholders with a 2015 year-end update and a summary overview of the Company's clinical trial plans for 2016. Respiratory Depression Pipeline Review, H2 2015 - 2 Companies & 6 Drug Profiles
M2 - Fri Nov 06, 10:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxch3b/respiratory) has announced the addition of the "Respiratory Depression - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals Drug Profiles - CX-1739 - CX-1942 - CX-2007 - CX-2076 - GAL-021 - tianeptine For more information visit http://www.researchandmarkets.com/research/kx...espiratory
Cortex Pharmaceuticals, Inc. to Present at the 14th Annual BIO Investor Forum
Marketwired - Mon Oct 19, 7:30AM CDT
Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, particularly obstructive and central sleep apneas and drug-induced respiratory depression, announces that it will be presenting at the 14th Annual BIO Investor Forum (www.bio.org). The conference is being sponsored by the Biotechnology Industry Organization and is being held on October 20 - 21, 2015 at the Parc 55 Hotel, San Francisco, California. The Company's CEO, James S. J. Manuso, Ph.D. is scheduled to present at 11:30 a.m. West Coast Time on Tuesday, October 20, 2015. Global Sleep Apnea Pipeline Review, H2 2015 - 5 Companies & 12 Drug Profiles
M2 - Fri Oct 02, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lb5jgx/sleep_apnea) has announced the addition of the "Sleep Apnea - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals - Rottapharm SpA - SK Biopharmaceuticals Co., Ltd. - Vivus, Inc. Drug Profiles - (phentermine topiramate) ER - CX-1739 - CX-2007 - CX-2076 - dexloxiglumide - dronabinol - GAL-021 - GAL-160 - GAL-160 Backups - itriglumide - SKL-N05 - Small Molecules for Sleep Apnea For more information visit http://www.researchandmarkets.com/research/lb...leep_apnea
Spinal Cord Injury - Pipeline Review H2 2015
M2 - Fri Oct 02, 5:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42rsjm/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Asubio Pharma Co., Ltd. - Athersys, Inc. - Axerion Therapeutics, Inc. - BioArctic Neuroscience AB - Cortex Pharmaceuticals, Inc. - Faron Pharmaceuticals Oy - FirstString Research, Inc. - Genervon Biopharmaceuticals, LLC - Grupo Ferrer Internacional, S.A. - Hemostemix Ltd - Histocell S.L. - K-Stemcell Co., Ltd. - Kadimastem Ltd. - Kringle Pharma, Inc. - Lipopharma Therapeutics SL - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuronax SAS - Omeros Corporation - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Q Therapeutics, Inc. - Quark Pharmaceuticals, Inc. - Remedy Pharmaceuticals, Inc. - RhinoCyte, Inc. - SanBio, Inc. - Sirnaomics, Inc. - StemCells, Inc. - Stemedica Cell Technologies, Inc. - TissueGene, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/42...pinal_cord
VRTX: 101.53 (+0.32), ATHX: 1.95 (-0.01), ACOR: 24.22 (+0.20), LPTN: 1.87 (unch), OMER: 11.51 (+0.14), CUR: 0.20 (-0.02)
Cortex Pharmaceuticals, Inc. to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Marketwired - Tue Sep 08, 4:05PM CDT
Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, particularly obstructive sleep and central apneas and drug-induced respiratory depression, announces that it will be presenting at the Rodman & Renshaw 17th Annual Global Investment Conference (www.rodm.com). The conference is being sponsored by H.C. Wainwright & Co. and is being held on September 8 - 10, 2015 at The St. Regis Hotel, New York, New York. The Company's CEO, James S. J. Manuso, Ph.D. is currently scheduled to present at 4:40 p.m. Eastern Time on Thursday, September 10, 2015. Huntington's Disease - Pipeline Review, H1 2015
M2 - Thu Sep 03, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q79g5p/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Acadia Pharmaceuticals - Addex Therapeutics - BioCrea - BioMarin Pharmaceutical - Cortex Pharmaceuticals - CrystalGenomics - EncephRx - Evotec - F. Hoffmann-La Roche - Galenea - Genervon Biopharmaceuticals - Ipsen - Isis Pharmaceuticals - Kadmon Corporation - KineMed - Living Cell Technologies - Marathon Pharmaceuticals - Medesis Pharma - Neuralstem - Neurimmune - Omeros - Oryzon Genomics - Pfizer - PharmatrophiX - Raptor Pharmaceuticals - reMYND - Sangamo BioSciences - Siena Biotech - Teva Pharmaceutical Industries - Treventis - Ultragenyx Pharmaceutical - uniQure - Vaccinex - Varine - Zenobia Therapeutics For more information visit http://www.researchandmarkets.com/research/q7...untingtons
ACAD: 31.37 (-0.50), BMRN: 92.44 (+0.43), RPTP: 6.78 (+0.03), ISIS: 57.56 (-0.28), SGMO: 4.41 (-0.03), TEVA: 53.86 (+0.44)
Cortex Pharmaceuticals raises USD721,180 from initial closing of private placement
M2 - Tue Sep 01, 10:46AM CDT
Biopharmaceutical company Cortex Pharmaceuticals (OTCQB:CORX) reported on Monday the initial closing of USD721,180 under a private placement of up to USD3m units at USD0.02103 per unit.
Cortex Pharmaceuticals, Inc. Announces Appointment of James S. J. Manuso, Ph.D., as President and Chief Executive Officer, Vice Chairman of the Board of Directors
Marketwired - Wed Aug 19, 7:30AM CDT
Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company"
, a leader in the discovery and development of innovative pharmaceuticals for the treatment of breathing disorders, today announced the appointment of James S. J. Manuso, Ph.D., 66, as President and Chief Executive Officer, as well as Vice Chairman and a member of the Board of Directors, of the Company. Dr. Manuso also has agreed to subscribe to purchase newly issued securities of the Company in an amount of $250,000, on terms to be agreed between the parties. Dr. Manuso is currently the Chairman, Chief Executive Officer and sole shareholder of Talfinium Investments, Inc., an investment company focusing on publicly traded companies in the biotechnology and pharmaceutical industries. Fragile X Syndrome Pipeline Review 2015 - 10 Companies & 20 Company Profiles
M2 - Fri Jul 10, 3:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js4sb7/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aelis Farma S.A.S. - Alcobra Ltd - Confluence Pharmaceuticals LLC - Cortex Pharmaceuticals, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Marinus Pharmaceuticals, Inc. - MI.TO. Technology S.r.L. - Neuren Pharmaceuticals Limited - Selvita SA Drug Profiles - acamprosate calcium - basimglurant - Bryostatin-1 - cercosporamide - CX-929 - Drugs to Inhibit mGluR5 for Fragile X Syndrome - flindokalner - gaboxadol - ganaxolone - Metadoxine ER - minocycline - NNZ-2591 - SEL-203 - Small Molecule for FXTAS - Small Molecule to Activate Epsilon PKC for Fragile X Syndrome - Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Small Molecules to Agonize 5-HT7 for Fragile X Syndrome - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - SRT-278 - trofinetide For more information visit http://www.researchandmarkets.com/research/js4sb7/fragile_x
MRNS: 1.45 (+0.07), ADHD: 5.01 (+0.01), LLY: 80.22 (-0.34)
Cortex Pharmaceuticals, Inc. Announces Partnership With the Knowledge Translation Strategy Unit of the Canadian Institutes of Health Research on the Use of Ampakines in the Alleviation of Respiratory Depression
Marketwired - Tue Jun 30, 8:02AM CDT
Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company"
is a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression. The Company owns patents and patent applications for certain families of chemical compounds that claim the chemical structures and their use in the treatment of various disorders. These patents cover, among other compounds, the Company's lead ampakines CX1739 and CX1942 and extend through at least 2028. Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 92.44 (+0.43), SRPT: 25.26 (+0.46), FOLD: 6.94 (+0.23)
Cortex Pharmaceuticals, Inc. Announces Publication of Research Results on the Use of Ampakines CX1739 and CX717 in the Treatment of Respiratory Disorders
GlobeNewswire - Mon May 04, 8:03AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
announces the recent publication of two key scientific papers co-authored by the Chairman of the Company's Scientific Advisory Board, Dr. John Greer, Ph.D. that show the positive effects of the Company's ampakines CX1739 and CX717 in treating respiratory distress in a perinatal premature rat pup model and a genetic mouse model of Pompe Disease. Cortex is a leader in developing drugs for respiratory disorders, particularly sleep apnea (both obstructive and central) and drug-induced respiratory depression. Cortex Pharmaceuticals, Inc. to Present at NewYorkBIO 25th Anniversary Conference
GlobeNewswire - Fri May 01, 8:00AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces that it will be presenting at the NewYorkBIO 25 Anniversary Conference (http://conference.newyorkbio.org). The conference will take place on May 4 - 5, 2015 at 10 on the Park @ Time Warner Center. Global Respiratory Depression Pipeline Review 2015 - 2 Companies & 8 Drug Profiles
M2 - Mon Apr 27, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59hbpn/respiratory) has announced the addition of the "Respiratory Depression - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals Drug Profiles - CX-1739 - CX-1942 - CX-2007 - CX-2076 - doxapram hydrochloride - GAL-021 - GAL-021 Successors - tianeptine For more information visit http://www.researchandmarkets.com/research/59...espiratory
Cortex Pharmaceuticals, Inc. Files December 31, 2014 Annual Report on Form 10-K; Provides Update on Current Status and Activities
GlobeNewswire - Mon Apr 06, 5:00AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
is a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression. Sleep Apnea Therapeutics Pipeline Review 2015 - 4 Companies & 11 Drug Profiles
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pw3nkj/sleep_apnea) has announced the addition of the "Sleep Apnea - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals - Rottapharm SpA - SK Biopharmaceuticals Co., Ltd. Drug Profiles - CX-1739 - CX-2007 - CX-2076 - dexloxiglumide - doxapram hydrochloride - dronabinol - GAL-021 - GAL-160 - GAL-160 Backups - itriglumide - SKL-N05 For more information visit http://www.researchandmarkets.com/research/pw...leep_apnea
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Report: 2015 Edition
M2 - Wed Feb 18, 6:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/26hd3f/copromotion_and) has announced the addition of the "Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering. The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace. Revised and updated 11th edition, includes: - Trends in co-promotion and co-marketing deals - Co-promotion and co-marketing agreement structure - Co-promotion and co-marketing contract documents - Top co-promotion deals by value - Top co-marketing deals by value - Most active co-promotion dealmakers - Most active co-marketing dealmakers Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2009 to end of December 2014. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in co-promotion and co-marketing dealmaking Chapter 3 - Overview of co-promotion deal structure Chapter 4 - Overview of co-marketing deal structure Chapter 5 - Leading co-promotion deals Chapter 6 - Leading co-marketing deals Chapter 7 - Big pharma co-promotion and co-marketing deals Chapter 8 - Co-promotion agreement contracts directory 2009-2014 Chapter 9 - Co-marketing agreement contracts directory 2009-2014 Companies Mentioned - Abbott - Allergan - Alnylam Pharmaceuticals - Ambit Biosciences - Amgen - Clarient - Columbia Laboratories - Cortex Pharmaceuticals - Eli Lilly - Embryome Sciences - Enanta Pharmaceuticals - Ironwood Pharmaceuticals - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe - NovaBay Pharmaceuticals - Novartis - Novo Nordisk - Procter & Gamble - Roche - Sagent Pharmaceuticals - Sanofi - Synta Pharmaceuticals - Takeda - Takeda Pharmaceutical - Targacept - Teva - Xenoport - Zogenix - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/26...motion_and
AMGN: 173.02 (+0.59), LLY: 80.22 (-0.34), CBRX: 7.36 (+0.45), ENTA: 23.41 (+0.01), AGN: 249.61 (-3.41), JNJ: 123.22 (-0.55), SNTA: 0.34 (+0.07), NVO: 46.18 (-0.28), IRWD: 13.36 (+0.02), MRK: 63.35 (-0.28), SGNT: 21.73 (+0.01), PG: 87.04 (+0.31), NVS: 82.08 (-0.72)
Cortex Pharmaceuticals, Inc. to Present at 7th Annual Biotech Showcase(TM) 2015
GlobeNewswire - Fri Jan 09, 7:07AM CST
Cortex Pharmaceuticals, Inc. (CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces that it will be presenting at Biotech Showcase(TM) 2015 (www.ebdgroup.com/bts/index.php). The conference is co-sponsored by the EBD Group and Demy-Colton Life Sciences Advisors and will be held at the Parc 55 Wyndham San Francisco-Union Square Hotel in San Francisco, California from January 12 - 15, 2015. 
